We rate BioNTech SE a hold due to volatile performance, weak growth, and premium valuation amidst COVID-19 vaccine reliance.
The U.S. Department of Health and Human Services (HHS) has announced $590 million in funding to Moderna to expedite the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback